Loading
Puxitatug samrotecan is a B7-H4 ADC targeting a checkpoint-like protein enriched in breast, ovarian, and endometrial cancers.
Puxitatug samrotecan is AstraZeneca's anti-B7-H4 IgG1 antibody carrying the topoisomerase I inhibitor AZ14170133 at a drug-to-antibody ratio of about 8 through a cleavable linker; the released payload traps topoisomerase I on DNA and crosses membranes to kill neighbouring cells. B7-H4 is a checkpoint-like protein enriched in breast, ovarian and endometrial cancers with minimal normal expression, and it is inversely correlated with PD-L1, offering a route into 'cold' tumours that immunotherapy fails to reach. The drug is in phase 2 dose optimisation on an every-3-weeks schedule in endometrial, ovarian and triple-negative breast cancer. Nausea, neutropenia and fatigue are the reported toxicities. Whether B7-H4 expression predicts response remains open. It targets a protein common in gynaecological and breast cancers that immunotherapy tends to miss.
Puxitatug samrotecan carries a camptothecin-derived TOP1 inhibitor; exatecan shown as the class representative.
Anti-B7-H4 IgG1 with TOP1 inhibitor. Connects to B7-H4 (VTCN1).
1.Antibody binds B7-H4 on the tumour cell surface
Source: clinicaltrials.gov/study/NCT05123482. Doses are for orientation; the current label governs.
| Adverse event |
|---|
| Nausea |
| Neutropenia |
| Fatigue |
Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United States | Investigational | not disclosed | - |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Puxitatug samrotecan" OR ABSTRACT:"Puxitatug samrotecan" OR TITLE:"AZD8205" OR ABSTRACT:"AZD8205") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Puxitatug samrotecan, not a curated reading list.
Shares Exatecan (and derivatives), Topoisomerase-I inhibitor payloads, AstraZeneca.
Shares A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies, Endometrial cancer, AstraZeneca, Ovarian cancer.
Shares B7-H4 (VTCN1), Endometrial cancer, Ovarian cancer.
Shares Exatecan (and derivatives), Topoisomerase-I inhibitor payloads, Triple-negative breast cancer (TNBC).
Shares Topoisomerase-I inhibitor payloads, Antibody-drug conjugate (ADC).
Shares A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies, Endometrial cancer, AstraZeneca, Ovarian cancer.